656. Clinical Characteristics of CMV Infection after Universal Valganciclovir Prophylaxis in Pediatric Renal Transplant Recipients
Session: Poster Abstract Session: Oh, Those Pesky Viruses!
Thursday, October 27, 2016
Room: Poster Hall
Background: Cytomegalovirus (CMV) infection is common in pediatric renal transplant recipients and approaches to prevention vary. In this study, characteristics of CMV infection after universal prophylaxis were analyzed.

Methods: A retrospective cohort of 93 pediatric kidney allograft recipients between 2008-2013, including 17-18 follow-up clinic visits per patient over two years, was analyzed. Clinical data included: demographics, immunosuppressive therapy, viral infection and disease, and biopsy results. CMV donor serostatus groups (D+ and D-) and donor/recipient serostatus groups (D+/R+, D+/R-, D-/R+, D-/R-) were compared for CMV infection and disease, EBV and BKV viral loads, and acute rejection using the one-way ANOVA.

Results: Among the 93 patients, 20.4% (19) were D+/R+, 40.9% (38) D+/R-, 9.7% (9) D-R+, and 29% (27) D-R-. Groups had no significant differences for patient demographics or immunosuppression. All patients received valganciclovir prophylaxis for at least 60 days, followed by prospective viral surveillance. Comparing the CMV donor serostatus groups, in the D+ group , 20/57 (35%) had CMV infection compared to 2/36 (5.6%) in the D- group (p=0.003). CMV disease occurred in 7/57 (12.3%) of D+ patients, compared to 1/36 (2.8%) of D- patients (p=0.23). Comparing the four donor/recipient serostatus groups, D-/R+ and D-/R- groups had a shorter duration until CMV clearance (mean±SD) at 26.5 ± 7.8 and 35 days, respectively, compared to the D+/R+ and D+/R- groups at 44.4 ± 29.8 and 86 ± 106.3 days. The D+/R- group exhibited the shortest interval until CMV viral loads were greater than 100 IU/mL at an average of 140.2 ±137.3 days and was the only group with children whose kidney biopsies demonstrated either borderline or cellular rejection (10.5%, 4/38 patients). There was a trend toward higher incidence of EBV and BKV viremia among CMV D+/R- patients.

Conclusion: The results of this study show an increased incidence of CMV infection in the D+ group, and increased acute rejection in the CMV D+/R- group. Although not statistically significant, pediatric CMV D+ patients also more often had CMV disease, earlier and longer duration of viremia, and EBV and/or BKV viremia, despite universal CMV antiviral prophylaxis and surveillance.

Pia Marie Cumagun, MD1, Grant Paulsen, MD2, Emily Mixon, MPH3, Brian Rha, MD, MSPH3, Chaitanya Allamneni, MD1, Dan Feig, MD PhD4, Karen Fowler, DrPH3,5 and Masako Shimamura, MD6, (1)University of Alabama School of Medicine, Birmingham, AL, (2)Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, (3)Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, (4)Division of Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, (5)Department of Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, (6)Division of Pediatric Infectious Diseases and Center for Vaccines and Immunity, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, Columbus, OH

Disclosures:

P. M. Cumagun, None

G. Paulsen, None

E. Mixon, None

B. Rha, None

C. Allamneni, None

D. Feig, None

K. Fowler, None

M. Shimamura, None

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.